Study treatment disposition
| . | MPD cohort (n = 52) . | Overall (N = 84) . |
|---|---|---|
| Number of CRd cycles received, n (%) | ||
| ≤12 | 33 (63.5) | 56 (66.7) |
| 13-18 | 6 (11.5) | 10 (11.9) |
| >18 | 13 (25.0) | 18 (21.4) |
| CRd discontinued, n (%) | 50 (96.2) | 81 (96.4) |
| Progressive disease | 26 (50.0) | 43 (51.2) |
| Adverse event | 10 (19.2) | 15 (17.9) |
| Withdrew consent | 1 (1.9) | 4 (4.8) |
| Completed treatment per protocol | — | 2 (2.4) |
| Other* | 13 (25.0) | 17 (20.2) |
| CRd active | 2 (3.8) | 3 (3.6) |
| . | MPD cohort (n = 52) . | Overall (N = 84) . |
|---|---|---|
| Number of CRd cycles received, n (%) | ||
| ≤12 | 33 (63.5) | 56 (66.7) |
| 13-18 | 6 (11.5) | 10 (11.9) |
| >18 | 13 (25.0) | 18 (21.4) |
| CRd discontinued, n (%) | 50 (96.2) | 81 (96.4) |
| Progressive disease | 26 (50.0) | 43 (51.2) |
| Adverse event | 10 (19.2) | 15 (17.9) |
| Withdrew consent | 1 (1.9) | 4 (4.8) |
| Completed treatment per protocol | — | 2 (2.4) |
| Other* | 13 (25.0) | 17 (20.2) |
| CRd active | 2 (3.8) | 3 (3.6) |
Includes patient/physician preference, patients proceeding to stem cell collection/transplantation or maintenance therapy, and noncompliance.